Skip to main content

iRhythm Technologies, Inc.

For the period ended Sep 30, 2025. Filed Oct 30, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Oct 30, 2025

IRTC$86.06-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

Nine Months Ended September 30,
20252024
(unaudited)
Cash flows from operating activities
Net loss$(50,130)$(111,956)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization15,48815,426
Stock-based compensation67,17759,970
Amortization of premium and accretion of discounts, net(2,165)(1,236)
Amortization of operating lease right-of-use assets4,2643,747
Amortization of debt discount2,3102,173
Change in fair value of strategic investments(3,889)(1,059)
Provision for credit losses and contractual allowances80,16152,737
Acquired in-process research and development2,29632,069
Loss on extinguishment of debt—7,589
Impairment charges2,479641
Other962217
Changes in operating assets and liabilities:
Accounts receivable(76,377)(68,680)
Inventory(6,450)(1,041)
Prepaid expenses and other current assets(2,817)8,165
Other assets(3,425)(614)
Accounts payable and accrued liabilities29,689(8,379)
Deferred revenue1,292(275)
Operating lease liabilities(6,214)(5,336)
Net cash provided by (used in) operating activities54,651(15,842)
Cash flows from investing activities
Purchases of property and equipment(34,619)(27,098)
Purchases of marketable securities(340,539)(2,426)
Maturities of marketable securities149,20098,700
Purchases of strategic investments(2,300)(55,000)
Purchases of acquired in-process research and development—(15,000)
Net cash used in investing activities(228,258)(824)
Cash flows from financing activities
Payment of SVB term loan and termination costs—(37,751)
Proceeds from Braidwell debt—75,000
Payments of issuance costs for Braidwell debt—(2,100)
Payment of Braidwell debt and termination costs—(78,660)
Proceeds from issuance of 2029 Notes—661,250
Payments of issuance costs for 2029 Notes—(17,424)
Purchases of capped call transactions—(72,407)
Purchase of treasury stock—(25,000)
Proceeds from issuance of common stock in connection with employee equity incentive plans9,6485,486
Net cash provided by financing activities9,648508,394
Effect of exchange rate changes(33)(8)
Net (decrease) increase in cash, cash equivalents and restricted cash(163,992)491,720
Cash, cash equivalents and restricted cash, beginning of period427,95536,173
Cash, cash equivalents and restricted cash, end of period$263,963$527,893

Condensed Consolidated Statements of Cash Flows (Continued)

Nine Months Ended September 30,
20252024
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents$255,605$519,535
Restricted cash$8,358$8,358
Total cash, cash equivalents and restricted cash$263,963$527,893
Supplemental disclosures of cash flow information:
Interest paid$9,919$6,389
Cash taxes paid$936$602
Cash paid for operating lease liabilities$11,791$11,283
Cash received from tenant improvement allowances$745$736
Non-cash investing and financing activities:
Property and equipment costs included in accounts payable and accrued liabilities$3,677$173
Capitalized stock-based compensation in property and equipment$4,170$5,530
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.